Mn Services Vermogensbeheer B.V. Trims Holdings in Moderna, Inc. (NASDAQ:MRNA)

Mn Services Vermogensbeheer B.V. lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 2.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 124,200 shares of the company’s stock after selling 3,100 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Moderna were worth $8,300,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of MRNA. Cedar Wealth Management LLC raised its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its position in Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC raised its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after purchasing an additional 96 shares in the last quarter. Claro Advisors LLC raised its holdings in Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares in the last quarter. Finally, McAdam LLC lifted its position in shares of Moderna by 1.1% in the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after purchasing an additional 117 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,184 shares of company stock valued at $238,531. Corporate insiders own 15.20% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $53.29 on Wednesday. The firm has a market cap of $20.48 billion, a P/E ratio of -3.46 and a beta of 1.69. Moderna, Inc. has a twelve month low of $52.08 and a twelve month high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $63.53 and a 200 day moving average of $100.31.

Analyst Ratings Changes

Several brokerages recently issued reports on MRNA. Sanford C. Bernstein started coverage on shares of Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a report on Wednesday, August 28th. TD Cowen dropped their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $94.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.